Regimen for treating prostate tissue and surgical kit for use in the regimen

Abstract

The present invention provides treatment regimens for treating diseased prostate tissue, including the steps of chemically ablating prostate tissue and coadministering an antiandrogen. In some embodiments, prostate tissue is chemically ablated by injection of ethanol, or an injectable gel comprising ethanol, into prostate tissue. Steroidal and non-steroidal antiandrogens are suitable antiandrogens. One suitable non-steroidal antiandrogen is bicalutamide. The treatment regimen is suitable for treatment of prostate tissue diseases including benign prostatic hyperplasia and prostatic carcinoma. The invention further provides a treatment regimen for treating benign prostatic hyperplasia, including the steps of damaging prostate tissue and coadministering an antiandrogen. Also provided by the present invention is a kit for treating a human male, including a means for necrosing prostate tissue, an antiandrogen drug, and a means for administering the antiandrogen drug. A kit including a first surgical device for delivering a chemoablation fluid to prostate tissue transurethrally, an antiandrogen drug such as bicalutamide, and a second surgical device for administering the antiandrogen drug, is further provided.

Description

REFERENCE TO RELATED APPLICATIONS [0001] This application is a divisional of U.S. application Ser. No. 10 / 193,716, filed Jul. 9, 2002 and entitled Regimen For Treating Prostate Tissue And Surgical Kit For Use In The Regimen the entire disclosure of which is hereby incorporated by reference. U.S. application Ser. No. 10 / 193,716 claims priority to U.S. Provisional Application No. 60 / 304,149 filed Jul. 10, 2001 and entitled “Method of Treating Prostate Tissue and Surgical Kit for Use in the Method,” the entire disclosure of which is hereby incorporated by reference, and also claims priority to U.S. Provisional Application No. 60 / 329,262 filed Oct. 12, 2001 and entitled “Surgical Instrument and Method,” the entire disclosure of which is hereby incorporated by reference.TECHNICAL FIELD [0002] The present invention relates to treatment regimens for treating diseased prostate tissue, and to surgical kits for use in a treatment regimen. [0003] Prostate disease is a significant health risk f...

AI Technical Summary

Problems solved by technology

Prostate disease is a significant health risk for males.

Symptoms include difficult urination, frequent urination, incomplete emptying of the bladder, and urgency.

Treatment by an inhibitor of 5α-reductase can reduce the production of DHT and slow the growth of prostatic tissue.

However, administration of an α1-adrenoreceptor antagonist treats only the symptoms of BPH, and does not treat the enlarged prostate itself.

Other undesirable side effects are also common, including weight gain, depression, fatigue, mood swings, and hot flashes.

The use of non-steroidal antiandrogens alone (i.e., not in combination with an LHRH analogue) has not been shown to be effective in the treatment of progressing prostate cancer.

Many hormonal therapies are accompanied by highly undesirable side effects, including impotence, loss of sexual desire, hot flashes, and gynecomastia (i.e., swelling or tenderness of breasts), among others.

Images